NVIDIA has recently launched a set of new microservices that allow healthcare enterprises worldwide to take advantage of the latest advances in generative AI from anywhere and on any cloud. The company has accelerated software development kits and tools that can enhance healthcare workflows for drug discovery, medical imaging and genomics analysis. Computer aided drug design (CADD) has played a pivotal role in the sector of pharmaceutical development. An array of techniques and innovations have come into the picture that are being able to provide acceleration and stimulation to the process of drug discovery and helping organizations in saving a significant amount of time.
“AI can assist in speed up of the development time and it is proved in the COVID vaccine development. On the other hand, if data analytics and compilation of data is done manually, it takes a lot of time. AI systems are able to process these operations faster and are also able to detect errors in the analytics and solve them during the process itself. So, AI is able to perform analytics faster and can also prove to be more intelligent. The data and the analytics provided by AI systems are more accurate”, Dr. Venkat Mattela, Founder, Ceremorphic Life Sciences.
Several factors come into play when we discuss about CADD and how it is making a mark in the pharmaceutical development sector. These factors, rather technology innovations need to work in unison for organizations to achieve the desired clinical results.
Implementation of 3D cell structures in drug design has been seen to represent significant advancements over traditional 2D cell cultures. This approach is aiming to to create more physiologically relevant models that mimic the in-vivo environment, enhancing the predictive accuracy of drug efficacy and toxicity. Integrating 3D cell structures into drug design is also enhancing the physiological relevance of preclinical testing, leading to more accurate predictions of drug efficacy and safety. This approach holds the promise of reducing the high attrition rates in drug development and accelerating the discovery of effective and safe therapeutics.
A company that is known in the field of 3D bioprinting and tissue engineering is Organovo. It specializes in creating functional human tissues using their proprietary 3D bioprinting technology, which is used for various applications in drug discovery and development, disease modeling, and regenerative medicine.
New drug discoveries are being hugely influenced by the advent of supercomputing systems that are able to eliminate all time constraints al across the process. The primary problem faced by organizations during new drug discovery is the time taken. The success rate for new drug discoveries was much lesser than the growing demand for pharmaceuticals in the market. With the AI based supercomputing systems, data collection and analytics have become much easier and far less time consuming. A process that would otherwise take months can now be performed within minutes.
In this regard, a company that has been able to development patented technologies in supercomputing for drug discovery is Ceremorphic Inc. The company has developed AI based supercomputing systems that are able to provide all required processes for drug discovery and help organizations in saving a lot of time.
In order to check the efficacy of design, it has to go through a manufacturing process. This is the final segment of drug design without which the process is incomplete. In this regard, Internet of Things (IoT) has played a revolutionary role. Several machinery could be interconnected by means of IoT and form an automated manufacturing process that requires no human intervention and saves a lot of time. Automated manufacturing processes have also helped in boosting pharmaceutical research because of faster rates of delivery and precision in supply chain processes.
One prominent pharmaceutical company that has incorporated manufacturing automation is Pfizer. Pfizer has integrated advanced automation technologies into its manufacturing processes to enhance efficiency, precision, and quality. Automation in Pfizer’s manufacturing facilities includes the use of robotics, advanced data analytics, and Internet of Things (IoT) devices to streamline production and ensure consistency in drug manufacturing.
Several other technology innovations apart from the above have disrupted pharmaceutical research and added new perceptions to computer aided drug design. In developing countries like India, these technology innovations have brought about a boom in pharmaceutical manufacturing as well. Many international manufacturers are now looking towards India for cheaper yet efficient place for pharmaceutical research and manufacturing. We will be able to see further progress in CADD in the years to come.
, CDSCO.jpg)
.jpg)